Avigan, David

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.

Berdeja, J. G., Madduri, D., Usmani, S. Z., Jakubowiak, A., Agha, M., Cohen, A. D., Stewart, A. K., Hari, P., Htut, M., Lesokhin, A., et al. (2021) · The Lancet

CAR-T cell therapy researchMultiple Myeloma Research and Treatments

Cited by 1,756

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study

Lesokhin, A. M., Ansell, S. M., Armand, P., Scott, E. C., Halwani, A., Gutierrez, M., Millenson, M. M., Cohen, A. D., Schuster, S. J., Lebovic, D., et al. (2016) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersLymphoma Diagnosis and Treatment

Cited by 1,001

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

Richardson, P. G., Weller, E., Lonial, S., Jakubowiak, A. J., Jagannath, S., Raje, N. S., Avigan, D. E., Xie, W., Ghobrial, I. M., Schlossman, R. L., et al. (2010) · Blood

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 861

Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up

Martin, T., Usmani, S. Z., Berdeja, J. G., Agha, M., Cohen, A. D., Hari, P., Avigan, D., Deol, A., Htut, M., Lesokhin, A., et al. (2023) · Journal of Clinical Oncology

CAR-T cell therapy researchMultiple Myeloma Research and Treatments

Cited by 663

Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma

Richardson, P. G., Weller, E., Jagannath, S., Avigan, D. E., Alsina, M., Schlossman, R. L., Mazumder, A., Munshi, N. C., Ghobrial, I. M., Doss, D., et al. (2009) · Journal of Clinical Oncology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 162

Lenalidomide enhances anti-myeloma cellular immunity

Luptakova, K., Rosenblatt, J., Glotzbecker, B., Mills, H., Stroopinsky, D., Kufe, T., Vasir, B., Arnason, J., Tzachanis, D., Zwicker, J. I., et al. (2013) · Cancer Immunology, Immunotherapy

Multiple Myeloma Research and TreatmentsImmunotherapy and Immune Responses

Cited by 162

Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence

Katsarou, A., Sjöstrand, M., Naik, J., Mansilla-Soto, J., Kefala, D., Kladis, G., Nianias, A., Ruiter, R., Poels, R., Sarkar, I., et al. (2021) · Science Translational Medicine

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 131

Phase 1b trial of pembrolizumab monotherapy for relapsed/refractory multiple myeloma: KEYNOTE‐013

Ribrag, V., Avigan, D. E., Green, D. J., Wise‐Draper, T., Posada, J. G., Vij, R., Zhu, Y., Farooqui, M. Z. H., Marinello, P., & Siegel, D. S. (2019) · British Journal of Haematology

Multiple Myeloma Research and TreatmentsCancer Immunotherapy and Biomarkers

Cited by 82

Pembrolizumab combined with lenalidomide and low‐dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE‐023 study

Mateos, M., Orlowski, R. Z., Ocio, E. M., Rodríguez‐Otero, P., Reece, D., Moreau, P., Munshi, N., Avigan, D. E., Siegel, D. S., Ghori, R., et al. (2019) · British Journal of Haematology

Multiple Myeloma Research and TreatmentsMultiple Sclerosis Research Studies

Cited by 73

Comprehensive Characterization of the Multiple Myeloma Immune Microenvironment Using Integrated scRNA-seq, CyTOF, and CITE-seq Analysis

Yao, L., Jayasinghe, R. G., Lee, B. H., Bhasin, S. S., Pilcher, W., Doxie, D. B., Gonzalez-Kozlova, E., Dasari, S., Fiala, M. A., Pita-Juarez, Y., et al. (2022) · Cancer Research Communications

Multiple Myeloma Research and TreatmentsSingle-cell and spatial transcriptomics

Cited by 45

BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma

Jagannath, S., Chanan-Khan, A., Heffner, L. T., Avigan, D., Zimmerman, T. M., Lonial, S., Lutz, R. J., Engling, A., Uherek, C., Osterroth, F., et al. (2011) · Blood

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 44

A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia

DeAngelo, D. J., Brunner, A. M., Werner, L., Avigan, D., Fathi, A. T., Sperling, A. S., Washington, A., Stroopinsky, D., Rosenblatt, J., McMasters, M., et al. (2018) · American Journal of Hematology

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 16